Impact of renal function on hydroxyurea exposure in sickle-cell disease patients.

Claire PressiatMarie-Georgine RakotosonAnoosha HabibiCaroline BarauRaphaele ArrouasseFrédéric GalactérosThomas StehléVincent AudardAnne HulinPablo Bartolucci

Published in: British journal of clinical pharmacology (2020)

Estimated GFR has an impact on the kinetics of hydroxyurea, and HU dose should be adapted accordingly. Angiotensin-converting enzyme inhibitor seems to have minor effect on HU PK in adults with sickle cell disease.

Keyphrases

sickle cell disease
angiotensin converting enzyme
end stage renal disease
angiotensin ii
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
patient reported